ORIGINAL RESEARCH
Published on 27 Aug 2025
First-line treatment with cadonilimab plus paclitaxel-platinum ± bevacizumab for persistent, recurrent, or metastatic cervical cancer: a retrospective real-world study
doi 10.3389/fonc.2025.1634779
- 186 views